Skip to main content

The Food and Drug Administration's Emergency Use Authorization: Lessons Learned from the Past to Guide the Future: Proceedings of a Workshop–in Brief

View Cover

Overview

Contributors

Description

The U.S. Food and Drug Administration (FDA) has responsibility for protecting public health by ensuring the safety, efficacy, and security of drugs, biological products, and medical devices. In certain declared emergencies, FDA has the option to authorize use of a new product or a new use of an approved product - an authority known as Emergency Use Authorization (EUA)- if it has reason to believe that the product may be effective and that its known benefits outweigh its known risks. By contrast, in non-emergency situations, applicants must demonstrate a product's safety and effectiveness through a lengthier, more extensive process.

On October 6-7, 2021, the Committee on Science, Technology, and Law of the National Academies of Sciences, Engineering, and Medicine convened a virtual workshop on the EUA process. At the workshop, presenters and participants examined FDA's recent and historic use of EUAs, discussed lessons learned during the COVID-19 pandemic, and considered how those lessons might inform future efforts. The workshop also highlighted emergency mechanisms used by other health regulators and considered how U.S. and global regulatory partners can strengthen cooperation in responding to global health emergencies. This publication summarizes the presentation and discussion of the workshop.

Topics

Suggested Citation

National Academies of Sciences, Engineering, and Medicine. 2021. The Food and Drug Administration's Emergency Use Authorization: Lessons Learned from the Past to Guide the Future: Proceedings of a Workshop–in Brief. Washington, DC: The National Academies Press.https://doi.org/10.17226/26441.

Import this citation to:

Publication Info

13 pages |8.5 x 11
DOI: https://doi.org/10.17226/26441
Contents
Rights

Copyright Information

The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:

  • Republish or display in another publication, presentation, or other media
  • Use in print or electronic course materials and dissertations
  • Share electronically via secure intranet or extranet
  • And more

For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.

Click here to obtain permission forThe Food and Drug Administration's Emergency Use Authorization: Lessons Learned from the Past to Guide the Future: Proceedings of a Workshop–in Brief.

Translation and Other Rights

For information on how to request permission to translate our work and for any other rights related query please click here.

Copyright.com Customer Service

For questions about using the Copyright.com service, please contact:

Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)
E-mail: info@copyright.com
Web: https://www.copyright.com
Stats

Loading stats for The Food and Drug Administration's Emergency Use Authorization: Lessons Learned from the Past to Guide the Future: Proceedings of a Workshop–in Brief...